Cargando…
Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy
Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of psoriatic systemic inflammation. The novel bi...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691657/ https://www.ncbi.nlm.nih.gov/pubmed/31448070 http://dx.doi.org/10.1177/2040622319865658 |
_version_ | 1783443425567178752 |
---|---|
author | Pithadia, Deeti J. Reynolds, Kelly A. Lee, Erica B. Liao, Wilson Wu, Jashin J. |
author_facet | Pithadia, Deeti J. Reynolds, Kelly A. Lee, Erica B. Liao, Wilson Wu, Jashin J. |
author_sort | Pithadia, Deeti J. |
collection | PubMed |
description | Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of psoriatic systemic inflammation. The novel biologic medication tildrakizumab is among the first drugs with specific action against IL-23 that has recently been approved by the United States Food and Drug Administration and the European Medicines Agency for moderate-to-severe psoriasis. Tildrakizumab has been shown in large randomized controlled trials to be effective in improving skin manifestations as well as enhancing quality of life outcomes in patients with psoriasis. Its simple dosing, prolonged duration of action, and mild adverse event profile make it a practical option for patients; however, only a small number of trials have investigated the clinical effectiveness of tildrakizumab, and long-term data regarding the drug’s efficacy and safety are currently limited. Hence, further research is needed to better understand the risks and benefits of tildrakizumab. This review summarizes and analyzes phase I, phase II, and phase III clinical trials that investigate the mechanism, pharmacokinetics, efficacy, and safety of tildrakizumab. It also identifies areas in which additional studies are warranted to further elucidate the advantages of tildrakizumab over other biologic therapies. |
format | Online Article Text |
id | pubmed-6691657 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-66916572019-08-23 Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy Pithadia, Deeti J. Reynolds, Kelly A. Lee, Erica B. Liao, Wilson Wu, Jashin J. Ther Adv Chronic Dis Psoriasis: From Pathophysiology to Treatment Psoriasis is a chronic inflammatory disorder that is clinically characterized by scaly cutaneous plaques. New evidence suggests that dysregulation of interleukin (IL)-23, a key cytokine in the T-helper-17 pathway, plays a vital role in the development of psoriatic systemic inflammation. The novel biologic medication tildrakizumab is among the first drugs with specific action against IL-23 that has recently been approved by the United States Food and Drug Administration and the European Medicines Agency for moderate-to-severe psoriasis. Tildrakizumab has been shown in large randomized controlled trials to be effective in improving skin manifestations as well as enhancing quality of life outcomes in patients with psoriasis. Its simple dosing, prolonged duration of action, and mild adverse event profile make it a practical option for patients; however, only a small number of trials have investigated the clinical effectiveness of tildrakizumab, and long-term data regarding the drug’s efficacy and safety are currently limited. Hence, further research is needed to better understand the risks and benefits of tildrakizumab. This review summarizes and analyzes phase I, phase II, and phase III clinical trials that investigate the mechanism, pharmacokinetics, efficacy, and safety of tildrakizumab. It also identifies areas in which additional studies are warranted to further elucidate the advantages of tildrakizumab over other biologic therapies. SAGE Publications 2019-08-12 /pmc/articles/PMC6691657/ /pubmed/31448070 http://dx.doi.org/10.1177/2040622319865658 Text en © The Author(s), 2019 http://www.creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Psoriasis: From Pathophysiology to Treatment Pithadia, Deeti J. Reynolds, Kelly A. Lee, Erica B. Liao, Wilson Wu, Jashin J. Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy |
title | Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy |
title_full | Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy |
title_fullStr | Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy |
title_full_unstemmed | Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy |
title_short | Tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy |
title_sort | tildrakizumab in the treatment of psoriasis: latest evidence and place in therapy |
topic | Psoriasis: From Pathophysiology to Treatment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691657/ https://www.ncbi.nlm.nih.gov/pubmed/31448070 http://dx.doi.org/10.1177/2040622319865658 |
work_keys_str_mv | AT pithadiadeetij tildrakizumabinthetreatmentofpsoriasislatestevidenceandplaceintherapy AT reynoldskellya tildrakizumabinthetreatmentofpsoriasislatestevidenceandplaceintherapy AT leeericab tildrakizumabinthetreatmentofpsoriasislatestevidenceandplaceintherapy AT liaowilson tildrakizumabinthetreatmentofpsoriasislatestevidenceandplaceintherapy AT wujashinj tildrakizumabinthetreatmentofpsoriasislatestevidenceandplaceintherapy |